Novartis Announces Positive CHMP Opinion For Kisqali
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible
With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies ...
Novartis has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by ...
As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss ...
Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...
BP’s program includes a novel PSMA-binding molecule that may be a potential next-generation radioligand therapy (RLT) for prostate cancer and is currently being studied in two investigator-initiated ...
Jasper Therapeutics, a biotech looking to make stem cell transplants less taxing and to treat immune-mediated diseases, ...
Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will ...
Novartis' Kisqali receives a positive recommendation from EMA's CHMP for adjuvant treatment of early breast cancer, showing a ...
Not every company is jumping onto the bandwagon and investing into weight loss drugs, however. One of the largest healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback